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Abstract
Induced pluripotent stem cells (iPSCs) are generated from terminally differentiated cells 
and have the potential to differentiate to any organs originated from the embryonic germ 
layers. Extensive effort has been made to establish protocols for direct in vitro conversion of 
human iPSCs (hiPSCs) to different cell types/organs. Importantly, hiPSCs can be generated 
from patients with known genetic mutations that predispose to high-risks of specific dis-
ease development. Thus, the hiPSCs technology provides unlimited resources for creating 
patient-specific disease models. hiPSC-derived three-dimensional “organoid” models have 
recently emerged as a powerful tool to recapitulate the physiologically-relevant process of 
disease progression in vitro. In this chapter, we will discuss the current advancement of 
organoid regeneration from hiPSCs and the applications of hiPSCs-derived organoids. The 
limitations and challenges of this approach will also be discussed here.
Keywords: disease modeling, induced pluripotent stem cells, organoid, organ-on-chip, 
tissue regeneration
1. Introduction
Induced pluripotent stem cells (iPSCs), generated directly from terminally differentiated 
cells [1], can differentiate toward all three embryonic germ layers - ectoderm, mesoderm, and 
endoderm. iPSCs can give rise to diverse cell types such as neurons, cardiomyocytes, and 
hepatocytes under defined conditions [2–4], and thus may provide a useful tool for study-
ing human organ development. Human iPSCs (hiPSCs) also open new avenues for patient-
specific or personalized disease modeling and therapies [5]. In the following sections, we will 
summarize the current advances in hiPSC-derived organoid differentiation and discuss the 
applications of these hiPSC-derived organoids in pre-clinical and clinical areas.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Generation of hiPSC
2.1. Protocols for generating hiPSCs
Dr. Yamanaka first reported the generation of hiPSCs from fibroblasts using four transcrip-
tional factors (POU5F1, SOX2, KLF4, and MYC) [6]. There are many protocols to further 
improve the original method. The first improvement was to minimizing the integration risks 
such as using non-integrating adenoviral vectors, transfection of mRNA, and using cell-pen-
etrating peptide-tagged reprogramming factors [7]. Transgene-free hiPSC generation proto-
cols have been published by multiple groups [8]. Using small molecules such as valproic acid, 
sodium butyrate, PD0325901, and others to create iPSCs has been reported [9–11]. Haase et al. 
reported a new non-transgenic protocol to generate hiPSCs from patient cord blood CD34+ 
cells using CytoTune™ Sendai reprogramming vectors under the exclusive usage of animal-
derived component-free (ADCF) materials and components [12]. Recently, non-integrative 
and non-viral mRNA reprogramming technology has been reported for hiPSC generation [13]. 
Rapid, efficient, and safe strategies which are compliant with standard Good Manufacturing 
Practice (GMP) regulations pave the way for hiPSC clinical applications.
2.2. Genome editing of hiPSCs
Genome editing in hiPSCs provides a valuable tool for disease modeling, mechanism study, 
and gene therapy. A line of technology utilizing engineered nucleases consisting of sequence-
specific DNA-binding domains attached to a non-specific DNA nuclease have been devel-
oped. These cutting-edge technologies allow researchers to manipulate entire genomes, 
including specific genes, intergenic regions, promoters, enhancers, silencers, and insulators. 
After zinc finger nucleases (ZFNs, first-generation) and transcription activator-like effector 
nucleases (TALENs, second-generation), the clustered regularly interspaced short palin-
dromic repeats (CRISPR/Cas9) technology is the third-generation editing tool. Despite the 
difference in the nucleases, the common mechanisms involve inducing DNA double-strand 
breaks (DSBs) in targeted DNA. Compared to TALEN and ZFN, CRISPR/Cas9 has become 
the system of choice because of its features such as high feasibility, high affordability, and 
precise targeting.
3. hiPSC-based tissue regeneration
hiPSC-derived organoids are valuable resources and tools for disease modeling, organ devel-
opment research, and therapy screening. The current established hiPSC-derived organoids 
are listed in Table 1 (adapted from Shi et al. [1]).
3.1. Ectoderm-derived tissues
Ectoderm is one of the three germ layers and the most exterior layer in the human embryo. 
It covers the outside of the embryo. The ectoderm gives rise to the central nervous system 
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(the brain and spinal cord), the peripheral nervous system, the sensory epithelia of the eye, 
ear, and nose, the epidermis and its appendages (the nails and hair), the mammary glands, 
the hypophysis, the subcutaneous glands, and the enamel of the teeth (Figure 1).
Organoids Applications Refs.
iPSC derived organoid model
Brain organoids Modeling autism disorder [14]
Modeling ALS disease [15]
Modeling Parkinson’s disease [16]
Modeling Zika virus infection [17]
Modeling Seckel syndrome [18]
Brain-region specific organoids Modeling Zika virus infection and human brain development disease [19]
Breast organoid Breast cancer research [20]
Cystic organoids Modeling Alagille syndrome, polycyctic liver disease and cystic 
fibrosis
[21]
Fallopian tube organoids Ovarian cancer research [22]
Liver bud Organ-bud transplantation for regenerative medicine [23]
Lung organoids Lung development and lung disease modeling [22, 25]
Pancreas Pancreatic disease model [26]
Retinal organoids Modeling glaucoma [27]
Table 1. Summary of hiPSC- and ESC-derived organoids, adapted from Shi et al. [1].
Figure 1. Summary of the organs originated from ectoderm.
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Figure 2. Specification of iPSC-derived neural tissue and exogenous factors used for derivation of organoids from iPS 
cells. Arrows indicate the temporal flow of tissue lineage as described by human development. Colored text denotes 
the small molecules that have been used to derive organoid models of each tissue (in gray) from iPSC spheroid or EB 
culture. Brain regions: CTX-Cortex and PNS: Peripheral nervous system. Growth factor and small molecules: BDNF, 
Brain-Derived Neurotrophic Factor; CNTF, Ciliary Neurotrophic Factor; CycA, Cyclophilin A; DSM, Dorsomorphin; 
EGF, Epidermal Growth Factor; FGF, Fibroblast Growth Factor; GDNF, Glial Cell-Derived Neurotrophic Factor; IWP2, 
WNT inhibitor; LDN, LDN-193189; NT3, Neurotrophin-3; SAG, Smoothened Agonist; SB, SB431542; SDF, Stromal cell-
derived factor; SHH, Sonic Hedgehog; PMP, Purmorphamine (Adapted from Lullo and Krigstein [29]).
3.1.1. Neuronal tissue regeneration
Several protocols have been developed for the de novo differentiation of hiPSC into cell types 
comprising the central nervous system (Figure 2). In general, protocols utilize either a mono-
layer culture condition, in which the neuroectoderm is further pushed toward spinal or cortical 
fates via neural rosette formation, or a three-dimensional culture system leading to the forma-
tion of neural organoids that again possess features of either cortical or spinal cell types. Here, 
we discuss the critical components of cortical and spinal organoid differentiation protocols.
Successful formation of a cortical organoid depends upon the appropriate temporal- and 
regional-specific expression of several proteins and transcripts. The first method of this dif-
ferentiation was presented by Lancaster et al. [28] in which the group relied upon intrinsic 
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self-organization, a droplet of gelatinous matrix, and spinning bioreactors to drive neural-
specific embryoid bodies toward developing cerebral structures.
Based on this initial protocol, several groups have published tangential methods that have 
improved the cortical organoid model. Pasca et al. [30] developed a differentiation method 
resulting in the generation of exclusively excitatory neurons reminiscent of the dorsal telen-
cephalon, as well as the derivation of non-reactive astrocyte-like cells. Dual SMAD inhibition 
has been used to induce neural-ectoderm differentiation in suspension, which results in high-
efficiency temporal and spatial organization of forebrain organoids [19, 30, 31]. Groups have 
also implemented transcriptional profiling to investigate the cell type composition of the mature 
organoid and to compare the overall maturity to that of the developing human brain [19, 30].
One of the most critical features for defining or characterizing a neuron from iPSCs is the neu-
ron’s function and physiology. Many groups have assayed the physiology of the developed 
organoids, implementing calcium imaging or patch-clamp physiology to describe spontaneous 
activity and expression of specific neurotransmitter receptors [19, 28, 30]. With the addition of 
an exogenous matrix built of hydrogel, another model of cerebral organoids could reach a larger 
size over a shorter duration in culture and express the oligodendroglial-like marker Olig2 [32].
In addition to modeling the brain and its specific regions, neural organoids have also 
been developed for modeling the immature spinal cord and motor nerve units [33, 34]. 
Experimentation with different extracellular matrix components and rigidity led to the dor-
sal-ventral patterning of neural cysts within nine days of culture [33], resulting in the imma-
ture modeling of the human spinal cord. Another group described a method for generating 
motor nerve organoids that developed a polarized axon fascicle [34]. Although the above pro-
tocols have their limitations, it is evident that organoid technology is rapidly moving toward 
the goal of forming nervous systems.
3.1.2. Non-neural tissue regeneration
3.1.2.1. Skin
Skin is the largest organ of the body and provides a barrier to protect the interior from the 
external environment. Human skin is the first barrier system that is vital for homeostasis. 
Protocols using hiPSCs to generate human skin or skin components have been developed. 
Regeneration of human skin typically composed of 2D and 3D methods. Keratinocytes are 
major epithelial components in the skin. Researchers have developed protocols using defined 
medium and chemical/cytokines generate keratinocyte them. Itoh et al. used a combination 
of retinoic acid and bone morphogenetic protein (BMP) 4 to induce ectoderm epithelial cell 
differentiation from the patient-derived hiPSCs [35]. The same group later generated hiPSC-
derived dermal fibroblasts, together with keratinocytes, to build 3D skin equivalents using an 
air-liquid interface culture [36]. The skin contains not only keratinocytes and fibroblasts, but 
also other skin appendages (eg. sweat glands, sebaceous glands, and hair follicle) and cells 
from different germ layer origins (fat cells, neurons, immune cells, muscles, blood vessels, and 
melanocytes. So far, the in vitro differentiation protocols have only been successful in develop-
ing dermal fibroblasts, keratinocytes, and melanocytes [37, 38]. Creating a full layer of skin 
tissue is still unfulfilled (Figure 3).
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3.1.2.2. Mammary gland
Mammary epithelial cells originate from non-neural/surface ectoderm cells, which co-exist 
with neural ectoderm cells at the same embryonic stage. Although mouse mammary gland 
development has been well studied, the human breast development is still poorly understood 
due to numerous differences between the mammary glands of the two species. In addition, 
questions regarding human mammary stem cell identity, mammary epithelial differentiation 
hierarchy, and the effects of ovarian hormones on mammary development are major obstacles 
for in vitro mammary gland regeneration.
Taking a cue from the understanding of human embryonic mammary gland development [39, 
40], Qu et al. conceptualized that the first step for in vitro induction of mammary differentia-
tion from hiPSCs was to pattern hiPSCs in to non-neural ectoderm, thus enriching mammary 
progenitors. The group developed a reliable two-step protocol to generate human mammary-
like organoids from hiPSCs [20]. These organoids express luminal, basal, and breast-specific 
markers. Despite these novel findings, this in vitro system needs to be improved to fully reca-
pitulate the formation of mammary ductal and alveolar structures.
3.2. Mesoderm-derived tissues
The mesoderm is formed through a process called gastrulation around the third week of embry-
onic development. Initially, mesoderm is segmented into three crucial compartments; the par-
axial mesoderm (PM), the intermediate mesoderm (IM), and the lateral plate mesoderm (LPM) 
(Figure 4). The PM, also known as presomitic or somitic mesoderm, gives rise to embryonic 
structures of the sclerotome, myotome, and dermomyotome, which later develop into many 
Figure 3. The hiPSC-based regeneration strategy for a full-layered human skin.
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adult tissues, including most of the axial skeleton, skeletal muscles, and connective tissues of the 
skin. The IM, which lies between the PM and LPM, differentiates into the urogenital duct system 
and gives rise to the kidneys, gonads, Wolffian (male) or Müllerian (female) ducts, fallopian tube, 
uterus, and the adrenal glands. The LPM is located on the side of the IM and is split horizontally 
into two layers: splanchnic mesoderm and somatic mesoderm. These layers contribute to the 
formation of the heart, blood vessels, and blood cells as well as to the connective tissue of the 
limbs and the space between these layers develop into the body cavity. This section summarizes 
the current hiPSC-derived 3D organoid differentiation research for tissues of mesodermal origin.
3.2.1. Kidney
Adult humans have a limited number of nephrons which do not increase during life but 
rather decay with age through attrition or disease. Currently, there is no known treatment 
accessible for nephron renewal in patients with chronic or end-stage kidney disease. Recent 
hiPSC-based tissue regeneration studies have provided the novel sources for nephron pro-
genitor cell (NPC) production and potentially kidney regeneration. This section summa-
rizes the current protocols to generate and maintain NPCs and 3D human kidney organoids.
The kidney is derived from IM which forms a urogenital ridge on either side of the aorta. 
Current multistep-directed differentiation methods are intended to recapitulate these cru-
cial stages of renal embryonic development. Studies for the critical transcriptional regulation 
process and signaling pathways contribute to the better understanding of each stage of renal 
development (Figure 5). Importantly, these studies enable us to recognize the factors that 
direct cell fate decisions and have been the basis for establishing the current differentiation 
protocols and culture conditions [41, 42].
hiPSC-derived 3D human kidney organoids that led to the generation of more complex and par-
tially self-organizing organoids [43–46] have been established (Figure 6). Takasato et al. [43, 44] 
Figure 4. Mesoderm subdivision and mesoderm-originated tissue development.
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reported the generation of self-organizing kidney organoids using CHIR99021 and fibroblast 
growth factor (FGF) 9/heparin in a monolayer culture followed by cell pelleting. The tran-
scriptional profiling of resulting organoids exhibits significant similarity to the first-trimester 
embryonic human kidney.
On the other hand, Morizane et al. [45] have patterned mesoderm into PM, IM, and LPMs 
and generated NPCs by mediating graded signals of GSK-3β inhibitor CHIR99021, Noggin, 
and Activin A. In this study, renal vesicle was formed by transiently treating the NPCs with 
the CHIR99021 and FGF9, following self-organizing differentiation into podocytes, proximal 
tubules, loop of Henle, and distal tubules in both 2D and 3D culture. Alternatively, a shorter 
Figure 6. Protocols for the directed differentiation of hiPSC into kidney organoid. The timescale is shown at the top 
(shortened after 20 days) and Day 0 marks the hiPSC stage. Oval images represent the obtained cell types-like in each 
stage, namely: Ep, epiblast; LPS, late primitive streak; NM, nascent mesoderm; PNM, posterior nascent mesoderm; PIM, 
posterior intermediate mesoderm; UE, ureteric epithelium; PA, pre-tubular aggregate; RV, renal vesicle. Growth factors 
and small molecules; BMP4, Bone Morphogenetic Protein bone 4; CHIR, CHIR99021; FGF, Fibroblast Growth Factor; 
RA, Retinoic Acid; VitD3, vitamin D3; WNT3A, Wingless Type Family member 3A; mTeSR1, defined iPSC medium and 
B27-Serum free cell culture supplements. Figure adapted from (Jacqueline Kai et al. [47]).
Figure 5. Schematic representation of the differentiation stages into NPCs and kidney organoids and markers that 
identify each stage. GATA3, GATA Binding Protein 3; LAM, laminin; LHX1, LIM homeobox 1; LPM, lateral plate 
mesoderm; MIXL, Mix Paired-Like Homeobox; OCT4, POU class 5 homeobox1; OSR1, odd-skipped related transcription 
factor 1; PAX2, paired box 2; PAX8, paired box 8; SALL1, spalt-like transcription factor 1; SIX2, SIX homeobox 2; SOX2, 
SRY-box 2;WT1, Wilms tumor 1.
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and more straightforward protocol has been developed by the group of Bonventre and col-
laborators. Bonventre group et al. demonstrated the formation of nephron-like structures as 
well as endothelial-like cells that were arranged into cords and expressed the endothelial 
markers CD31 and von Willebrand factor [46].
3.2.2. Cardiomyocytes
Cardiovascular disease remains the leading cause of death worldwide. It encompasses an 
extensive range of clinical conditions due to genetics, physiologic and metabolic circumstances 
as well as drug toxicity. Most heart diseases are associated with severe damage to, or loss of, 
cardiomyocytes (CMs), and mammalian CMs have a limited regenerative capacity [48]. The 
recent advancements in the field of hiPSC-derived CMs (hiPSC-CM) offer unique opportuni-
ties for not only disease modeling and personalized drug efficacy/toxicity screening but also 
for stem cell-based cardiac regenerative therapy [49–51].
CMs arise from mesoderm, which is further specified into cardiac mesoderm and cardiac pro-
genitor cells by three families of extracellular signaling molecules: WNT, FGF and TGFβ super-
family ligands (WNT3a, bone BMP4, Nodal and Activin A). The expression of these ligands in 
a spatiotemporal manner defines the mesodermal cell fate and prime CM differentiation [52, 
53]. Several groups successfully mimic these signaling processes in vitro to generate hiPSC-
CM, which is summarized in Table 2 (adapted from Smith et al. [54] and Burridge et al. [55]).
Method Culture 
condition
Differentiation 
format
Mesoderm 
induction
Cardiac 
specification 
factors
Cardiac 
Differentiation 
factors
Ref.
Suspension EB 
in StemPro34
Knock-
out serum 
Replacement 
(KSR)/FGF2
StemPRo 34 Activin A, BMP4
FGF2
VEGFA, DKK1 VEGFA, FGF2 [56]
VEGFA, DKK1, 
SB431542
Dorsomorphin
[57]
IWR1 Tri-iodothyrinine [58]
Monolayer 
Differentiation
Monolayer on 
Matrigel with 
MEF
RPM1 plus B27 Activin A, BMP4 RPM1 plus B27 RPM1 plus B27 [59]
Activin A, 
BMP4, FGF2
Noggin, RAi, 
DKK1
DKK1 [60]
RPM1 plus 
B27(−insulin)
Activin A, 
BMP4, FGF2
VEGFA, DKK1 VEGFA, FGF2 [61]
(KSR)/FGF2 on 
MEF
LI-APEL Activin A, 
BMP4, FGF2, 
VEGFA, SCF
LI-BEL LI-BEL [62]
mTeSR RPM1 plus B27 Activin A, BMP4 IWR1 or IWP4 RPM1 plus B27 [63]
mTeSR+ROCKi RPM1 plus 
B27(−insulin)
CHIR IWR1 or IWP4 RPM1 plus B27
Chemically 
defined E8
CDM3 CHIR/WNTC59 CDM3 CDM3 [65]
Table 2. Methods for hiPSC-CM differentiations (adapted from Smith et al. [54] and Burridge et al. [55]).
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The first generation of CM differentiation was established using ESCs and successfully 
applied to hiPSCs. While the traditional embryoid body protocol engaged serum-derived 
spontaneous differentiation into CM, its efficiency was very low, (∼1–5%). The second gen-
eration of CM differentiation aimed to recapitulate the embryonic developmental sequences 
in vitro by  modulating stage-specific activation/inhibition of signaling pathways with recom-
binant protein, details described in Table 2. At the molecular level, each stage of iPSC-CM 
differentiation is characterized by sequential expression of specific sets of genes [53]. These 
protocols were much more efficient; however, they were expensive and exhibited high batch-
to-batch variation.
The third-generation hiPSC-CM protocol is composed of sequential modulation of the Wnt 
signaling pathway: activation at an early stage with small molecules such as CHIR-99021 
and then inhibition at a late stage with small molecules such as IWP2 [64–66]. These mono-
layer-based directed differentiation protocols generate CMs with high efficiency. On the other 
hand, maturation of these CMs became a major challenge for the use of de novo CMs in heart 
research, especially for disease modeling and drug testing [67, 68]. Thus, several studies used 
prolonged cell culture, electrical stimulation, mechanical stretch or hormonal stimulations to 
induce CM maturity [69–72].
hiPSC-CM technology has transformed the field of cardiovascular research, especially the 
study of inherited and acquired cardiovascular diseases. Several heart diseases including long 
QT syndromes, catecholaminergic polymorphic ventricular tachycardia, and familial hyper-
trophic cardiomyopathy have been modeled using hiPSC-CM [73–75]. Patient-specific CM 
regeneration may hold the promise for stem cell-based cardiac therapy.
3.2.3. Fallopian tube
Ovarian cancer is the leading cause of gynecologic cancer-related deaths in the United States. 
Fallopian tube epithelia (FTE) has been identified as the origin of ovarian cancer [76]. The dis-
covery of serous tubal intraepithelial carcinoma (STIC) lesions, a preneoplastic finding in the 
fallopian tube fimbriae of patients with BRCA mutations, supports the model of FTE origin of 
serous “ovarian” carcinoma [77].
Yucer et al. [22] developed a hiPSC-derived 3D human FTE model, mimicking the FTE 
development process via various intermediate stages toward mature FTE in 3D organoid 
culture. Female reproductive tract structures including fallopian tube epithelium arise from 
the Müllerian duct in parallel to the urinary system from IM of the urogenital ridge in the 
posterior primitive streak. Therefore, Yucer et al. [22] recapitulated Müllerian development 
starting with IM generation and further developed into fallopian tube epithelial precursors 
using pro-Müllerian growth factors. Each step of this differentiation is monitored through 
the expression of established markers (Figure 7). Further differentiation of the fallopian 
tube epithelial lineage was attained on a 3D growth platform, which enables the FTE organ-
oid to self-organize into a convoluted luminal structure with secretory and ciliated cellular 
components [22].
Tissue Regeneration106
hiPSC-derived 3D-FTE organoids model offers a faithful in vitro platform to investigate the 
fallopian tube origin of ovarian cancer and to explore early cancer pathogenesis and pro-
gression. This platform can also be used to study high-risk germline mutations including 
BRCA1/2, to identify the molecular signature and genetic alteration involved in carcinogen-
esis and ultimately uncover novel drug targets.
3.3. Endoderm-derived tissues
The endoderm gives rise to the epithelial lining of the gastrointestinal and respiratory tracts; 
the parenchyma of the tonsils, the liver, the thymus, the thyroid, the parathyroids, and the 
pancreas; the epithelial lining of the urinary bladder and urethra; and the epithelial lining of 
the tympanic cavity, tympanic antrum, and auditory tube (Figure 8).
Figure 7. Schematic of iPSC derive FTE organoid model. The stepwise differentiation of FTE via various intermediate 
stages which are characterized by specific molecular signatures. BMP4, Bone Morphogenetic Protein bone 4; CHIR, 
CHIR99021; E2, Estrogen: P4, Progesterone; WNT, Wingless Type Family member.
Figure 8. Summary of organs originated from endoderm.
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3.3.1. Small intestine, stomach, and colon
The small intestinal tissue is composed of a single-layer of epithelial cells which form a lumen 
that is surounded surrounded by connective tissue. Functionally, the small intestine plays a 
central role in digestion and absorption of nutrients. There are different cell lineages (entero-
cytes, goblet cells, Paneth cells, tuft cells and enteroendocrine cells) in the small intestine with 
various functions such as exocrine, absorption, and protection. While diseases of the small 
intestine, such as tumor, inflammatory bowel disease (IBD), lactose intolerance are common, 
the study of these diseases have encountered difficulties due to the limitation of in vitro model-
ing systems.
The protocols used for intestinal organoid differentiation have been published by different 
groups [78, 79]. In general, hiPSCs are directed to differentiate into definitive endoderm fol-
lowed by intestinal fate specification and development using Wnt3A and FGF4. Intestinal 
organoids, usually cultured in Matrigel, show a polarized, columnar epithelium that is pat-
terned into villus-like structures and crypt-like proliferative zones that expresses intestinal 
stem cell markers. The epithelium contain functional enterocytes, as well as goblet, Paneth 
and enteroendocrine cells with a layer of mesenchymal cells. Yu et al. [80] reported a refined, 
non-Matrigel scaffold and 3D intestinal organoid culture protocol. The matrix-free system 
may improve the yield, decrease the time, and facilitate high-throughput approaches. The 
protocols used to generate intestines from hiPSCs are summarized in Figure 9.
Gastric ulcer and gastric cancer affect 10% of the world’s population and there is no experi-
mental model of the normal human gastric mucosa. The lack of proper models has hindered 
mechanistic studies, preventive approach testing, and disease modeling. Kyle et al. developed 
the first protocol directing hiPSCs to 3D gastric organoids by manipulating FGF, WNT, BMP, 
retinoic acid and EGF signaling pathways [81]. These organoids formed primitive gastric 
gland- and pit-like domains, proliferative zones containing LGR5-expressing cells, surface 
and antral mucous cells, and a diversity of gastric endocrine cells.
Figure 9. The protocols used to generate intestinal organoids using hiPSCs.
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Recent studies have successfully generated colonic organoids from hiPSCs. Following the 
similar differentiation path to intestinal organoids, hiPSCs were sequentially differentiated 
into definitive endoderm, hindgut endoderm, and colonic organoids. The colonic organoid 
differentiation was conducted in a Matrigel 3D culture. Jorge et al. [82] modified the proto-
col used for small intestinal organoid differentiation by adding BMP2 in the Matrigel cul-
ture stage. BMP signaling can promote posterior fate in human gut tube cultures. Another 
group [83] reported a different approach by supplementing the inhibitors CHIR99021 and 
LDN193189, and EGF in the Matrigel culture stage. These hiPSCs-derived colonic organoids 
exhibit crypt-like structure formed by a polarized epithelium consisting of colon stem cells, 
goblet, and endocrine cells and a layer of supportive mesodermal tissue.
3.3.2. Lung
The regeneration of lung epithelial cells/organoids has applications in regenerative medi-
cine, modeling of lung disease, drug screening and studies of human lung development. The 
lung is composed of endoderm-derived epithelial cells surrounded by mesenchymal-derived 
stromal cells. Lung epithelial cell differentiation follows the path of definitive endoderm to 
anterior foregut endoderm. Then the Nkx2.1+ endoderm will bud from the ventral side of the 
anterior foregut to form the primitive lung bud, which will form the respiratory tree. Signals 
from the mesenchyme to the epithelium are critical in cell specification, determination, and 
differentiation, and are essential for proper development and maturation of the lung [84].
A number of studies show the differentiation of hiPSCs into lung epithelial cells in 2D [84–88]. 
However, 3D lung organoid differentiation has become the trend. Briana et al. [24] reported 
a breakthrough in the stepwise differentiation of human lung organoids from hiPSCs that 
consist of both epithelial and mesenchymal components. These lung organoids possess upper 
airway-like epithelium with basal cells and immature ciliated cells surrounded by smooth 
muscle and myofibroblasts as well as an alveolar-like domain with appropriate cell types. 
Later, Chen et al. reported the generation of lung bud organoids (LBOs) that contain meso-
derm and pulmonary endoderm and develop into branching airway and early alveolar struc-
tures after xenotransplantation and Matrigel 3D culture [89].
The application of acellular lung matrices has been reported in 3D lung tissue reconstruction. 
Decellularized lung matrix supports the culture and lineage commitment of hiPSC-derived 
lung progenitor cells [90]. The rotating bioreactor was also used to provide an air-liquid inter-
face, which is a potent inducer of type I epithelial differentiation for both hiPSC-Alveolar 
epithelial type (AT) II and ATI cells [91]. The bioreactor system provides a method for large-
scale production of alveolar epithelium for tissue engineering and drug discovery. Another 
improvement for lung regeneration from hiPSCs is the use of biomaterials [25].
4. Application of iPSC-based tissue regeneration
hiPSC-derived cells or organoids are becoming promising resources for disease modeling and 
therapeutical applications. In general, somatic cells from patients can be reprogrammed to 
hiPSCs. In turn, patient-specific hiPSCs can be converted into target organs using established 
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protocols. These in vitro derived organs can be used for multiple purposes, including patient-
specific disease modeling, drug testing, therapy screening, and transplantation.
4.1. Personalized disease modeling
The biggest advantage of the hiPSC technology lies in its patient-specific feature. hiPSC-derived 
3D organoid models have recently emerged as a powerful tool to recapitulate and investigate the 
physiologically-relevant process of disease onset and progression in vitro. This model system lever-
ages the self-renewal and multi-lineage differentiation capability of multipotent stem cells and 
their intrinsic self-organization regenerative ability to form 3D tissue architecture. Importantly, 
hiPSCs can be derived from patients with known hereditary genetic mutations that are associated 
with a higher risk of a particular disease. This provides a valuable approach to determine whether 
additional genetic alterations are needed to interact with the known mutations, thereby contribut-
ing to disease susceptibility, initiation, and progression [92].
Several hiPSC-derived, inherited human disease models have been used to reproduce cancers 
associated with those high-risk patients [93, 94]. A hiPSC-derived osteosarcoma model for 
Li-Fraumeni syndrome has yielded promising results in displaying disease pathogenesis and 
carcinogenesis events commonly found in relevant human cells [95]. Cystic Fibrosis (CF) is 
an inherit disease of secretory glands. Among all the organs, pancreas is the earliest and most 
severely affected organs impacted by CF. hiPSC-derived pancreatic epithelial cells can be used 
to study personalized CF development [96]. Kyle et al. [81] used hiPSC-derived gastric organ-
oids to model the pathophysiological response of the human stomach to H. pylori infection. In 
addition, Miguel et al. reported using hiPSC-derived colonic organoids to model family APC 
mutation-associated colon cancer initiation [83]. More and more hiPSCs-based disease models 
will be established.
4.2. Therapeutic applications
4.2.1. Drug screening
Organoids differentiated from patient-derived hiPSCs can be used to build a screening plat-
form to develop and validate therapeutic approaches. hiPSC-derived organoids have a line of 
features that make them suitable models. Using a defined protocol, hiPSC-derived organoids 
become an unlimited resource for a specific patient. The in vitro direction of organ differentia-
tion allows the rapid and robust generation of organoids with identical features. Most impor-
tantly, the organoids are 3D based mini-tissues that consist of multiple cell types, and that 
recapitulate the tissue structures in vivo. Thus, the drug screening results are more applicable 
in vivo. As an example, hiPSC-based drug screening for Huntington’s disease has been estab-
lished [97] developed. The applications of hiPSCs that have been reprogramed from patients 
of heritable, genetic diseases has been summarized by Wonhee Suh in a review paper [98].
Biomimetic tissues on a chip have been developed for drug discovery [99]. Organ-on-a-chip 
is based on microfluidic technology and has been proposed as a novel cell-based assay tool 
in pre-clinical studies. Furthermore, the concept of body-on-a-chip, which is stands for mul-
tiple organs connected through microfluid devices, can mimic multiple interactions between 
organs [100]. Applying hiPSC research to the concept of organ-on-a-chip has provided a 
promising future for the development of the patient-specific body-on-a-chip [101]. Drug 
Tissue Regeneration110
screening is no longer a process that is limited by the responses of targeted organ, it can also 
provide an evaluation of systemic responses.
4.2.2. Gene therapy
The nature of the disease and desired genetic modification, efficiency and accuracy of gene 
repair methodology, as well as cell state will determine the success of gene therapy [102]. In 
theory, monogenic diseases dictated by a dysfunctional copy of the causative gene would be 
reversed by introducing a wild-type copy of the gene into cells [103, 104]. Over 80% of rare 
diseases are considered to have a genetic origin [105], which means the precise gene edit-
ing technologies can be practically used to correct these genetic factors. The application of 
genome editing technologies in therapeutic trials have been reported in many diseases, such 
as retinal diseases [106], lysosomal storage diseases [107], arthritis [108], and neurological 
disorders [109, 110]. In contrast, polygenic diseases that require simultaneous multiple altera-
tions of the genome are more challenging to treat with gene therapy [111].
Gang et al. presented a highly efficient and reproducible protocol to edit the genome of hiP-
SCs through the combined use of the CRISPR/Cas9 RNA-guided nuclease and piggyBac (bac-
terial artificial chromosome) transposase [112]. Their method can result in efficient, targeted 
genome editing and concurrent “scarless” transgene excision. Satoru et al. reported using gene 
editing with engineered site-specific endonuclease technology to treat dominant-negative 
disorders by targeting only the mutant allele while leaving the normal allele intact [113]. 
Using precise gene editing technology to correct gene mutations from hiPSCs generated from 
patients combined with  hiPSC differentiation into target cells/organs for transplantation pro-
vides an immense promise for the future of gene therapy (Figure 10).
Figure 10. The summary of gene therapy applying precise genome editing technology in hiPSCs.
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4.2.3. Transplantation
Given that hiPSCs are pluripotent stem cells which can be propagated unlimitedly and proto-
cols for their differentiation into different cells/organoids have been established, hiPSC-derived 
micro-tissues are a potentially innovative material source for transplantation. In addition, 
immune rejection will be minimized when essentially returning the hiPSC-derived tissue to the 
original patient. For mature cells that have no or limited regenerative ability, such as cardio-
myocytes, neurons, and pancreatic cells, hiPSC-derived cell/organoids are especially valuable 
for tissue repair. There are a series of clinical studies evaluating hiPSC-cells/organoids for treat-
ment of neural degeneration, diabetes, heart failure, and retinal cells [114]. Although research 
on the application of hiPSCs in therapy have shown encouraging progress, there are some con-
cerns involving the safety of hiPSC-based cell transplantation. Tumor risk and acquired gene 
mutations are major concerns.
5. Future and challenges
The original protocol to generate hiPSCs involves four transcriptional factors, but this method 
is not suitable because of its effect on genome integrity via the introduction of additional 
plasmids with exogenous genes. To make hiPSCs and their derivatives applicable for clinical 
uses, many improvements have been made to optimize the method for iPSC generation. The 
integration-free and chemical reprogramming protocols have been developed to minimize 
the risk of jeopardizing genome integrity [115, 116].
In general, the genetic nature of a disease, the molecular editing platform used, the deliv-
ery method, and the targeted cells and organs are all factors that influence the efficacy of 
treatment and determine the likelihood of clinical benefits [117]. The CRISPR/Cas9 molecular 
scissor system has been used to edit the genomes of a diverse array of mammalian cell types 
and organisms with high efficiency and precision. Determining and overcoming the actual 
frequency of off-target activities is challenging, yet critical to the application of the technol-
ogy in gene therapy. CRISPR/Cas9 technology allows the study of complex genetic diseases, 
including human cancer, in which multiple mutations and chromosomal translocations are 
present in the genome [118, 119].
The potential application of hiPSC technology in cancer studies has been proposed, based on 
the idea of reprogramming cancer cells via hiPSC technology to cancer stem cell (CSC) state. 
CSCs are well-known as the origin of tumor development, the seeds for distant metastasis, 
and are critical in therapeutic resistance. Reprogramming the malignant cells back to their 
original state before the oncogenic transformation occurs [120], may provide tools for explor-
ing the mechanisms of tumor initiation and progression in vitro, for studying the heteroge-
neity and origin of CSCs, and for producing cancer type-specific drug discovery. However, 
these reprogramming methods remain a challenge because of the cancer-specific epigenetic 
state and chromosomal aberrations of cancer cells.
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